ECSP23091202A - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
ECSP23091202A
ECSP23091202A ECSENADI202391202A ECDI202391202A ECSP23091202A EC SP23091202 A ECSP23091202 A EC SP23091202A EC SENADI202391202 A ECSENADI202391202 A EC SENADI202391202A EC DI202391202 A ECDI202391202 A EC DI202391202A EC SP23091202 A ECSP23091202 A EC SP23091202A
Authority
EC
Ecuador
Prior art keywords
trex1
modulators
compositions
treating
compounds
Prior art date
Application number
ECSENADI202391202A
Other languages
English (en)
Inventor
Jonathan Wilson
Julian Levell
Aaron Coffin
Avinash Khanna
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of ECSP23091202A publication Critical patent/ECSP23091202A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proveen compuestos de fórmula (I): y sales farmacéuticamente aceptables y composiciones de los mismos, que son útiles para tratar una variedad de afecciones asociadas a TREX1.
ECSENADI202391202A 2021-05-05 2023-12-05 Moduladores de trex1 ECSP23091202A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163184460P 2021-05-05 2021-05-05

Publications (1)

Publication Number Publication Date
ECSP23091202A true ECSP23091202A (es) 2024-03-01

Family

ID=82016366

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202391202A ECSP23091202A (es) 2021-05-05 2023-12-05 Moduladores de trex1

Country Status (20)

Country Link
US (1) US20240262814A1 (es)
EP (1) EP4333985B1 (es)
JP (1) JP2024516289A (es)
KR (1) KR20240035385A (es)
CN (1) CN117561251A (es)
AU (1) AU2022269596A1 (es)
BR (1) BR112023022917A2 (es)
CA (1) CA3217421A1 (es)
CL (1) CL2023003253A1 (es)
CO (1) CO2023016367A2 (es)
CR (1) CR20230569A (es)
DO (1) DOP2023000241A (es)
EC (1) ECSP23091202A (es)
ES (1) ES3049639T3 (es)
IL (1) IL308220A (es)
JO (1) JOP20230275A1 (es)
MX (1) MX2023013045A (es)
PE (1) PE20241334A1 (es)
PH (1) PH12023553004A1 (es)
WO (1) WO2022235725A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4054719B1 (en) 2019-11-04 2026-02-11 Revolution Medicines, Inc. Ras inhibitors
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
CA2879245A1 (en) * 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
MA54386B1 (fr) * 2018-12-06 2023-08-31 Constellation Pharmaceuticals Inc Modulateurs de trex1
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
IL308220A (en) 2024-01-01
WO2022235725A1 (en) 2022-11-10
AU2022269596A1 (en) 2023-11-16
CR20230569A (es) 2024-01-22
CN117561251A (zh) 2024-02-13
ES3049639T3 (en) 2025-12-17
JP2024516289A (ja) 2024-04-12
PH12023553004A1 (en) 2024-03-11
KR20240035385A (ko) 2024-03-15
PE20241334A1 (es) 2024-07-03
CO2023016367A2 (es) 2024-02-05
EP4333985A1 (en) 2024-03-13
BR112023022917A2 (pt) 2024-01-23
US20240262814A1 (en) 2024-08-08
CA3217421A1 (en) 2022-11-10
EP4333985B1 (en) 2025-07-30
MX2023013045A (es) 2024-01-19
JOP20230275A1 (ar) 2023-11-02
CL2023003253A1 (es) 2024-05-03
DOP2023000241A (es) 2024-02-29

Similar Documents

Publication Publication Date Title
CL2021001461A1 (es) Moduladores de trex1
MX2024012029A (es) Moduladores del transductor de señal y activador de la transcripción y usos de los mismos
CO2024010861A2 (es) Moduladores stat y usos de los mismos
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
CL2023003312A1 (es) Inhibidores de nlrp3
CO2025000035A2 (es) Composiciones farmacéuticas que comprenden inhibidores de helicasa wrn
CL2024001346A1 (es) Agonistas inversos del pparg y usos de los mismos
ECSP23091202A (es) Moduladores de trex1
MX2020010508A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados.
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CL2023000594A1 (es) Compuestos heterocíclicos
CO2022010878A2 (es) Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
DOP2025000044A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CL2025001654A1 (es) Compuestos novedosos como moduladores de la inhibición de nlrp3
CL2025002615A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
ECSP23088732A (es) Moduladores de trex1
DOP2011000053A (es) Agentes antifungicos